UW-OncoPlex - Cancer Gene Panel
UW-OncoPlex is a multiplexed gene sequencing panel that detects mutations in tumor tissue in 262 cancer-related genes (listed in the methods below). The panel includes genes related to cancer treatment, prognosis, and diagnosis. The test uses next-generation "deep" sequencing to detect most classes of mutations, including single nucleotide variants, small insertions and deletions (indels), gene amplifications, and selected gene-fusions. In addition, microsatellite instability status is reported for colorectal cancers.
Methods (assay version 5)
The following genes are sequenced on an Illumina instrument to detect single nucleotide variants, small insertions and deletions, gene amplifications, and selected translocations: ABCB1*, ABCC4*, ABCG2*, ABL1, ABL2, AKT1, AKT2, AKT3, ALK**, APC, AR, ARAF (NEW), ARID1A (NEW), ASXL1, ATM, ATRX, AURKA, AURKB, AXL, BAK1, BAP1, BARD1, BCL2, BCL2L11, BCOR, BCORL1 (NEW), BCR*, BRAF**, BRCA1, BRCA2, BRIP1, CALR, CBL, CBLB, CBLC (NEW), CCND1, CCNE1, CDH1, CDK12 (NEW), CDK4, CDK6, CDK8, CDKN1A, CDKN2A, CEBPA, CHD1, CHEK1, CHEK2, CREBBP, CRLF2, CSF1R, CSF3R (NEW), CTNNB1, CUX1 (NEW), CYP1B1*, CYP2C19*, CYP2C8*, CYP2D6*, CYP3A4*, CYP3A5*, DAXX, DDR2, DEPDC5, DNAJB1, DNMT3A, DOCK7, DPYD, EGFR, EIF3A, EIF3E (NEW), EML4*, EPHA3, EPHA5, EPHB2, EPHB6, ERBB2, ERBB3, ERBB4, ERCC2, ESR1 (NEW), ESR2*, ETV6**, EZH2, FAM175A, FANCA (NEW), FBXW7, FCGR1A, FCGR2A, FCGR3A*, FGFR1**, FGFR2**, FGFR3**, FGFR4, FKBP1A (NEW), FLT1, FLT3, FLT4, FOXA1, GAB2, GATA1, GATA2, GATA3, GLI1, GNA11, GNAQ, GNAS, GRIN2A, GRM3, GSTP1*, H3F3A, HDAC4, HIF1A, HNF1A, HRAS, HSPH1*, IDH1, IDH2, IGF1R, IKZF1, IL7R, ITPA*, JAK1, JAK2, JAK3, KDM6A, KDR, KIF5B*, KIT, KRAS, LRP2*, MAN1B1*, MAP2K1, MAP2K2, MAP2K4, MAPK1, MC1R, MCL1, MDM2, MDM4, MED12, MEN1, MET, MIOS, MITF, MLH1**, MLH3, MLL (KMT2A)**, MPL, MRE11A, MSH2**, MSH6**, MTAP, MTHFR*, MTOR (NEW), MUTYH, MYC, MYCL1, MYCN, MYD88 (NEW), NBN, NF1, NF2, NKX2-1, NOTCH1, NOTCH2, NPM1, NPRL2, NPRL3, NQO1*, NRAS, NRP2*, NTRK1**, NTRK2**, NTRK3**, PAK1, PALB2, PAX5, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CB (NEW), PIK3R1, PLK1, PLK2, PLK3, PLK4, PML*, PMS2, POLD1, POLE, PRPF40B, PTCH1, PTEN, PTPN11, PTPRD, RAC1 (NEW), RAD21 (NEW), RAD51C, RAD51D, RAF1, RARA**, RB1, RET, RHEB (NEW), RICTOR, ROS1**, RPS14, RPTOR (NEW), RSPO2** (NEW), RSPO3** (NEW), RUNX1, SETBP1 (NEW), SF1, SF3B1, SHH, SLC19A1*, SLC22A2*, SLCO1B3*, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMC1A (NEW), SMC3 (NEW), SMO, SOD2*, SPOP, SPRY4, SRC, SRSF2, STAG2 (NEW), STK11, SUFU, SULT1A1*, SUZ12, TACC3, TACSTD2, TET1 (NEW), TET2, TET3 (NEW), TFG*, TGFBR2, TMPRSS2*, TP53, TPMT*, TRRAP, TSC1, TSC2, TYMS*, TYR, U2AF1, (U2AF35), U2AF2, (U2AF65), UGT1A1*, UMPS*, VHL, WT1, ZBTB16, and ZRSR2.
*Selected regions only sequenced, **Selected introns sequenced in addition to all coding regions
Gene Fusions and Rearrangements Detected (assay version 5)
- ALK fusions (including ALK-EML4, ALK-KIF5B, ALK-TFG, ALK-C2orf44)
- BCR-ABL (common p190 and p210 fusions only)
- BRAF fusions
- DNAJB1- PRKACA fusions
- FGFR3 fusions
- MLL rearrangements
- RET fusions
- ROS1 fusions
- NTRK1 fusions
- NTRK2 fusions (NEW)
- NTRK3-ETV6 fusions (NEW)
- RSPO2 fusions (NEW)
- RSPO3 fusions (NEW)
- TMPRSS2 fusions
Microsatellite Instability Analysis
Microsatellite instability (MSI) status is reported for all colorectal cancer cases. MSI is detected using methods described in Salipate et al. 2014 Clin Chem. (2014) 60:1192-9.
4 - 6 weeks
- UW MEDICAL CENTER
- LABORATORY MEDICINE - GENETICS LAB
- 1959 NE PACIFIC ST, ROOM NW220
- SEATTLE, WA 98195-7110
- Formalin-Fixed Paraffin Embedded Tumor Tissue (FFPE)
- Purified DNA
- Peripheral Blood
- Bone Marrow
Tissue samples (FFPE): Send EITHER (a) slides, OR (b) tissue block: (a) Instructions for slide specimens: 1 slide at 4-micron thickness stained with hematoxylin-and-eosin AND 10 unstained, non-baked slides at 10-micron thickness (a minimum of 5 unstained slides is acceptable). Unstained slides can be on charged or uncharged slides. Note: Sections should contain as much tumor tissue as possible. (b) Instructions for tissue block specimen: Provide complete tissue block containing tumor tissue. If there is more than one tissue block, please provide the block that has the greatest amount of tumor tissue. Tissue block will be returned at completion of testing. Ship at room temperature.
Note: In order to ensure that enough DNA is obtained, the minimum acceptable tissue area is 10 square millimeters when ten 10-micron slides are supplied (1 cubic millimeter of tissue). Tissue sections should contain as much tumor tissue as possible; to ensure detection of all types of mutations, there should be at least 10% tumor cells in the tissue area processed for DNA.
Purified DNA: (Reference hematoxylin-and-eosin stained slide and pathology report required): 5 ug minimum. Ship specimen refrigerated for overnight delivery.
Blood: 6 mL blood in LAVENDER TOP (EDTA) tube. Ship specimen refrigerated for overnight delivery. Specimen can be held for up to 24 hours before shipping if refrigerated.
Bone Marrow: 1 to 2 mL Bone Marrow in LAVENDER TOP (EDTA) tube. Ship specimen refrigerated for overnight delivery. Specimen can be held for up to 24 hours before shipping if refrigerated.
For further details regarding specimen collection, handling and transport, see the Laboratory Medicine Online Test Guide for OPX
- Indicate on the requisition any previous molecular testing that has been performed on the sample
CPT Codes & Pricing
For pricing information, contact Reference Laboratory Services at 1-800-256-0893
No mutation detected.
For further information:
Other tests offered by the Genetics and Solid Tumor Diagnostic Laboratory
- Lab telephone: (206) 598-6429
- Supervisor: Robert Livingston, Ph.D.
- Director: Colin C. Pritchard, M.D., PhD.
- Director: David Wu, M.D., Ph.D.
- Director: Christina Lockwood, Ph.D.
- Director: Eric Konnick, M.D., M.S.
- Director: Brian Shirts, M.D., Ph.D.
- Director: Jonathan Tait, M.D., Ph.D.
Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. (2010) 11:31-46.
Pritchard CC, Salipante SJ, Koehler K, Smith C, Scroggins S, Wood B, Wu D, Lee MK, Dintzis S, Adey A, Liu Y, Eaten KD, Martins R, Stricker K, Margolin K, Hoffman N, Churpek J, Tait JF, King MC, Walsh T. Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. The Journal of Molecular Diagnostics (2014) 16:56-67.
Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem. (2014) 60:1192-9.